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The monoclonal antibody Ca37, 
developed against Candida albicans 
alcohol dehydrogenase, inhibits the 
yeast in vitro and in vivo
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Leire Martin-Souto1, Aitor Rementeria1, Mahmoud A. Ghannoum2, Beth Burgwyn fuchs3, 
eleftherios Mylonakis3, Fernando L. Hernando1 ✉ & Andoni Ramirez-Garcia1
Candida albicans is a commensal yeast able to cause life threatening invasive infections particularly in 
immunocompromised patients. Despite the availability of antifungal treatments, mortality rates are 
still unacceptably high and drug resistance is increasing. We, therefore, generated the Ca37 monoclonal 
antibody against the C. albicans alcohol dehydrogenase (Adh) 1. Our data showed that Ca37 was able 
to detect C. albicans cells, and it bound to Adh1 in yeast and Adh2 in hyphae among the cell wall-
associated proteins. Moreover, Ca37 was able to inhibit candidal growth following 18 h incubation 
time and reduced the minimal inhibitory concentration of amphotericin B or fluconazole when used 
in combination with those antifungals. In addition, the antibody prolonged the survival of C. albicans 
infected-Galleria mellonella larvae, when C. albicans was exposed to antibody prior to inoculating G. 
mellonella or by direct application as a therapeutic agent on infected larvae. In conclusion, the Ca37 
monoclonal antibody proved to be effective against C. albicans, both in vitro and in vivo, and to act 
together with antifungal drugs, suggesting Adh proteins could be interesting therapeutic targets 
against this pathogen.
Candida albicans is a commensal microorganism typically present in the mucosal and gastrointestinal tracts of 
humans. However, in some cases, it can become pathogenic, causing diseases that range from superficial mucosal 
infections to invasive candidiasis, which comprises bloodstream infection (candidemia) and/or deep-seated can-
didiasis1. Candida spp. are among the most isolated pathogens in hospital settings and in fact, C. albicans is the 
fungus most associated with nosocomial infections, with a mortality rate that can reach up to 50%2. Due to the 
increasing number of immunocompromised patients and the aging of the population, it is tempting to speculate 
that in the following years infections due to this fungus may increase.
Currently, only four antifungal classes are available against invasive candidiasis, and drug resistance has been 
described to all of them3. In fact, since the appearance of the echinocandins more than 10 years ago, no new class 
of antifungal drugs has been introduced. There is, therefore, an urgent need for new treatments to combat fungal 
infections4, and inhibitory antibodies are a promising avenue. Monoclonal antibodies (mAb) are being studied as 
a possible therapy for candidiasis and other fungal infections, either alone or in combination with antifungals5–8.
Our research group focused on the interaction between the host and C. albicans, and found several pro-
teins related to yeast pathogenicity9–11. One of these, alcohol dehydrogenase (Adh), despite its metabolic role 
in the cytoplasm, has been identified as an allergen and antigen12 that is also located on the cell wall13–15, where 
it may play a role as an adhesin, binding the host’s fibronectin16 and serum plasminogen17. C. albicans Adh1 
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protein has also been associated with the promotion of cancer because it catalyzes the production of carcinogenic 
acetaldehyde18–21.
Therefore, considering the importance of the Adh1 of C. albicans and the fact that the homology between the 
human and fungal Adh1 is low (32% of identity, as compared by BLAST (https://blast.ncbi.nlm.nih.gov/Blast.
cgi), a tool for gene and protein sequence alignment comparison), the aim of this work was to produce and study 
the effect of an anti-Adh1 (Ca37) mAb on the growth and viability of C. albicans, and to test its potential use in 
therapy.
Results
Characterization of the specificity of the Ca37 monoclonal antibody. C. albicans specificity of 
the antibody was examined on cytosolic and cell wall-associated protein (CWP) fractions using both yeast and 
hyphae morphologies. In addition, the cross-reactivity with human cells was studied using a soluble protein 
fraction of the human monocytes THP-1 cell line, and the ability of the mAb to recognize other Candida genus 
species was also tested. The western blot (WB) performed over the sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) membrane showed a very similar banding pattern between the cytosolic fractions of 
both fungal yeast and hyphal morphologies (Fig. 1a), whereas the pattern of CWP fraction was different between 
Figure 1. Western blotting of Candida albicans proteins recognized by Ca37 monoclonal antibody. SDS-PAGE 
western blotting of (a) cytosolic and (b) cell wall-associated proteins fractions of the fungus and (c) of THP-1 
human monocyte cells. (d) Recognition of the Ca37 over the yeast cell wall-associated protein fraction of other 
Candida species. 2-DE western blotting of C. albicans (e) yeast and (f) hyphal cell wall-associated proteins. The 
identified spots are marked in red. (g) Growth curves of C. albicans using four different media: minimum media 
(MM) with different glucose concentrations (0.5%, 1% and 2%) and Sabouraud Dextrose broth (SDB). The time 
of yeast cell collection is marked in red. (h) Expression of the cell wall-associated proteins recognized by Ca37 
in exponential and stationary phase grown in the mentioned four media. The red arrow marks the experimental 
molecular weight of the Adh1 protein. Blots have been cropped in order to facilitate the comparison among 
them; full-length blots are presented in Supplementary Figs. 1 and 2.
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yeasts and hyphae (Fig. 1b). The Ca37 antibody did not bind to any THP-1 cytosolic protein (Fig. 1c), and regard-
ing the ability to bind other Candida species, the mAb recognized bands from Candida parapsilosis, Candida 
glabrata and Candida auris CWP fraction (Fig. 1e), although the pattern was different in each species. Only C. 
albicans yeast and hyphal CWP fractions were used for two-dimensional electrophoresis (2-DE) and WB anal-
ysis, because of the importance of this fraction owing to its closer association with the surrounding medium. In 
this fraction, the most immunoreactive spots were identified as alcohol dehydrogenase (Fig. 1e,f). However, the 
most immunoreactive spot from the yeast extract was identified as Adh1, whereas the one in hyphae extract was 
determined to be Adh2 (Table 1).
On the other hand, to test the expression of the C. albicans Adh1 in different media and growth phases, CWP 
from yeasts collected in exponential (8 h) and stationary phases (27 h) using 4 different media (minimal medium 
(MM) supplement with 0.5%, 1% and 2% glucose and Sabouraud Dextrose Broth (SDB), Fig. 1g) were analysed 
(Fig. 1h). Adh was present in all the texted conditions. A differential expression of some bands was observed 
in different conditions, being, in general, more reactive in stationary phase, but no significant differences were 
found. The original WB of all the blots presented in Fig. 1 can be found in Supplementary Figs. 1 and 2.
In addition, an indirect immunofluorescence (IIF) assay was carried out to study whether the fungal proteins 
identified on the CWP fraction were accessible to antibody recognition on the cell surface (Fig. 2). Ca37 bound 
to C. albicans only when cells were pre-treated with sodium metaperiodate or when the incubation time was 
extended to 18 h, indicating that the mAb needs the elimination of the carbohydrates achieved by oxidation with 
metaperiodate or extended incubation times in order to penetrate the carbohydrate layer of the cell wall and 
detect the Adh proteins. In the second case (18 h incubation), the antibody was able to bind both yeast and hyphal 
cells, although not every cell was bound by the mAb, nor was the entire cell surface covered by the mAb (Fig. 2c), 
indicating low epitope availability. We also performed the IIF assay over an ADH1 null mutant strain22, but in 
both cases (with metaperiodate treatment and extended time of incubation) a recognition of the Ca37 mAb was 
observed (Fig. 2d,e, respectively) in a similar way than in its wild type (data not shown) and the control strain.
In vitro assessment of Ca37 antibody. After confirming antibody recognition, the effect on C. albicans 
NCPF 3153 and CECT 13062 strains growth was tested. Data showed that exposure to Ca37 had no significant 
effect on fungal growth (Fig. 3a,b). It is possible that active yeast division could hamper the action of the anti-
body during growth; therefore, inhibition was also studied by incubating C. albicans with the mAb in Dubelcco’s 
phosphate buffer saline (DPBS) prior to counting the colony-forming units (CFUs) grown in agar plates. In this 
case, a significant reduction in C. albicans CFU numbers was observed, 10 µg/mL being the most effective mAb 
concentration, which achieved a maximum of 90% inhibition (P = 0.001 in the case of NCPF 3153 strain and 
P < 0.0001 in the case of CECT 13062) (Fig. 3c,d). Therefore, this concentration was used with the rest of the 
strains, achieving an inhibition of between 70 to 90%, while the immunoglobulin (Ig) G1 isotype control exhib-
ited no effect (Fig. 3e). The effect of Ca37 on yeast germination was also analysed. Although only three of the five 
strains showed a significant inhibition, the germination of all strain was inhibited between 6 and 20% (Table 2).
Since Ca37 demonstrated inhibitory activity towards C. albicans, a possible synergy with current standard 
of care antifungal agents was investigated. The combined effects with antifungals that target different structures 
was explored: amphotericin B inhibits ergosterol synthesis and fluconazole targets cytochrome P450. Although 
the CECT 13062 strain was already susceptible to amphotericin B (The European Committee on Antimicrobial 
Susceptibility Testing-EUCAST breakpoints for antifungals, v. 9.0) the addition of the antibody reduced the min-
imal inhibitory concentration (MIC) value of amphotericin B to half, from 0.5 to 0.25 mg/L (Fig. 4a). In the 
case of fluconazole, the concentration of the antifungal needed to inhibit 50% of the growth of UPV 93–153 
fluconazole-resistant strain was also reduced by half (from 32 to 16 mg/L) in the presence of 20 and 10 µg/mL 
of Ca37 (Fig. 4b). Fractional inhibitory concentration index (FICI) values were 0.55 for the combination of the 
anti-Adh1 with amphotericin B and 1 with fluconazole, both cases showing an additive effect.
Effect of the Adh1 on fungal virulence, and effect of Ca37 antibody against the yeast in vivo. 
The role of C. albicans Adh1 in virulence and the ability of the Ca37 antibody to inhibit this pathogen were tested 
in vivo using Galleria mellonella as an invertebrate infection model (Fig. 5). To establish the infection profile of 
an ADH1 mutant strain, larvae were initially infected with an ADH1 knockout strain, which was found to be 
less virulent, with prolonged survival compared to the DAY286 parental strain (P = 0.0198; Fig. 5a). The larvae 
infected with the ADH1 single allele revertant strain also showed an increased survival rate (P = 0.035) compared 
to the parental strain.
To study the inhibitory effect of the antibody, C. albicans (CECT 13062) cells were pre-treated with Ca37 
before their inoculation. A fluconazole control and an IgG1 isotype control were also included (Fig. 5b). Data 
showed that the antibody was able to significantly reduce the mortality of C. albicans infected larvae (P = 0.0001), 











1 P43067.1 Alcohol dehydrogenase 1 5 16 368 6.02/37 5.1/46
2 KGU32026.1 Alcohol dehydrogenase 2 2 6 128 6.25/37 6.31/40.5
Table 1. LS/MS-MS identification of the protein spots detected by Ca37 monoclonal antibody in the cell wall-
associated protein fraction western blots.
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the mean survival time being 4–5 days longer than the G. mellonella group receiving non-treated yeast. The effect 
on the survival of the highest Ca37 concentration was only one half-day shorter than that of fluconazole. As 
expected, the IgG1 isotype control did not have any effect (P = 0.3173).
Figure 2. Visualization of the Ca37 monoclonal antibody-mediated recognition of Candida albicans yeast 
and hyphae through indirect immunofluorescence. C. albicans NCPF 3153 strain incubated (a) for 1.5 h with 
the Ca37 monoclonal antibody, (b) for 1.5 h with the Ca37 monoclonal antibody after treatment with 50 mM 
sodium metaperiodate and (c) for 18 h with the Ca37 monoclonal antibody. C. albicans ADH1 knockout strain 
incubated (d) for 1.5 h with the Ca37 monoclonal antibody after treatment with 50 mM sodium metaperiodate 
and (e) for 18 h with the Ca37 monoclonal antibody.
5Scientific RepoRtS |         (2020) 10:9206  | https://doi.org/10.1038/s41598-020-65859-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
To test the therapeutic effect of Ca37, the mAb was injected immediately after infecting the larvae with C. albi-
cans. As seen in Fig. 5c, G. mellonella treated with Ca37 or fluconazole survived a day longer than those larvae not 
treated with the mAb after C. albicans inoculation. The difference between non-treated larvae and larvae treated 
with Ca37 was statistically significant (P = 0.0052). Thus, showing that that the mAb was able to inhibit the C. 
albicans infection in the infection model, an encouraging finding.
Discussion
Fungi present a particularly challenging pathogen to combat given that, like human cells, they are eukaryotic; 
and finding viable cellular targets that do not have adverse effects on the host is difficult. Proteins belonging to 
the cell wall of fungal pathogens have been studied as potential target for antifungal therapies, since this structure 
is not present in human cells. Alcohol dehydrogenase is a cytoplasmic enzyme, needed for glucose and ethanol 
processing, and plays an essential role in yeast metabolism; although, its role in the fungal cell wall is still unclear. 
It has been described previously as an antigen and adhesin12,16, but it may also play other roles yet to be elucidated. 
Figure 3. Effect of the Ca37 monoclonal antibody on Candida albicans growth. Growth curves of (a) NCPF 
3153 strain and (b) CECT 13062 strain treated with Ca37 mAb, measured at 600 nm. The number of mAb 
concentrations studied have been reduced in order to allow a better visualization of the results. Growth 
inhibition of (c) NCPF 3153 strain (P values were 0.108 for 20 μg/mL, 0.001 for 10 μg/mL, 1 for 2 and 1 μg/mL, 
0.002 for 0.1 μg/mL, 0.016 for μg/mL and 0 for 0.001 μg/mL) and (d) CECT 13062 strain (P values were <0.0001 
for 20, 10, 2, and 1 μg/mL, 0.037 for 0.1 μg/mL, 1 for 0.01 μg/mL and 0.001 for 0.001 μg/mL) in presence of a 
wide range of Ca37 mAb concentrations, and (e) growth of five C. albicans strains were inhibited by 10 μg/mL 
Ca37 mAb. P values were <0.0001 for NCPF 3153 and CECT, 0.02 for UPV 15–170, 0.001 for UPV 15–172 and 
0.003 for UPV 15–172. A non-specific IgG1 isotype control was included. Results are presented as percentage 
of growth in comparison with the control (100%). N = 3 in all cases. All data were normally distributed, 
therefore one way ANOVA was used with Bonferroni’s (for homogenous variances) or Tamhane’s T2 (for non-
homogenous) corrections for multiple comparisons. Alpha value was set to 0.05 at least. Statistically significant 
differences in comparison to the non-treated control are marked as *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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In fact, other metabolic proteins such as enolase have also been found on the cell wall and studied as therapeutic 
targets and even as a vaccine23.
Recently, monoclonal antibodies have been studied as alternative therapies in order to overcome the toxicity 
of current antifungal agents and the emergence of resistance to them. In fact, one anti-Candida mAb, named 
Mycograb, directed against heat shock protein 90, was developed, and showed a positive outcome in patients 
suffering from invasive candidiasis in combination with amphotericin B24. Unfortunately, due to concerns over 
its safety for use in humans, its application was discouraged in Europe8. This does not, however, mitigate the 
development of new mAbs against new or alternate fungal targets.
C. albicans Adh has recently been associated with a high immunogenic capacity and the conversion of mono-
cytes into pro-inflammatory macrophages25. In addition, Adh inhibition may play a role in the reduction of fungal 
proliferation. Therefore, an anti-Adh1 monoclonal antibody, Ca37, was developed against C. albicans Adh1 pro-
tein and its effect on the viability of the yeast studied.
The mAb developed in this study specifically recognized Adh1 on yeast and Adh2 on hyphae CWP fraction. 
These two proteins share an 84% homology; therefore, the detection of these similar proteins is probably due to 
cross-reactivity. This result contrasts with those found by others, such as Pitarch et al.13, who found Adh1 in both 
yeast and hyphae CWP fraction, whereas Adh2 was detected in the cytosolic extract of hyphae26. In this study, 
we found that neither Adh1 nor any other human protein was detected by Ca37 antibody, as observed by western 
20 µg/mL 10 μg/mL
NCPF 3153 6.11 (±1.35) 8.35 (±1.34)*
CECT 13062 9.31 (±2.73) 10.18 (±3.34)
UPV 15–170 17.38 (±0.35)* 9.06 (±4.41)
UPV 15–171 16.20 (±1.48)** 9.92 (±2.56)*
UPV 15–172 19.11 (±3.61) 18.58 (±7.12)
Table 2. Germination inhibition (in percentage) of five different Candida albicans strains in the presence of 
20 and 10 μg/mL of Ca37 monoclonal antibody. Statistically significant differences in comparison to control 
(no mAb added), P value for NCPF 3153 (10 μg/mL) was 0.02, for UPV 15–170 (20 μg/mL) 0.013 and for UPV 
15–171 0.002 in the case of 20 μg/mL and 0.02 in the case of 10 μg/mL. N = 3 in all cases. All data were normally 
distributed, therefore one way ANOVA was used with Bonferroni’s (for homogenous variances) or Tamhane’s 
T2 (for non-homogenous) corrections for multiple comparisons. Alpha value was set to 0.05 at least.*P ≤ 0.05, 
**P ≤ 0.01.
Figure 4. Additive effect of Ca37 monoclonal antibody with antifungals. (a) CECT 13062 strain and 
amphotericin B and (b) UPV 93–153 strain and fluconazole were used. MIC values are marked in red. The grey 
scale indicates the rate of inhibition, being higher in the case of light grey (100 to 40% of inhibition) and lower 
in the dark one (20 to 0% of inhibition).
7Scientific RepoRtS |         (2020) 10:9206  | https://doi.org/10.1038/s41598-020-65859-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
blot using THP-1 protein extract. This is not surprising, as the homology between human Adh1 protein and C. 
albicans Adh1 and Adh2 proteins is considerably low, 32% and 30%, respectively (BLAST alignment tool). This 
opens a possibility of using Ca37 mAb in humans once its efficacy is proven. Regarding the cross-reactivity with 
other Candida species, Ca37 mAb was able to recognize C. parapsilosis, C. glabrata and C. auris. As the homology 
between Adh protein of those species with C. albicans Adh proteins is high, between 73 to 85% (as analysed by 
BLAST) this fact was expected. The differences observed in the band pattern between the four species might be 
due to posttranscriptional modifications, because their theoretical molecular weight is similar (around 37 kDa 
for C. albicans, C. glabrata and C. auris and 43 kDa for C. parapsilosis; http://candidagenome.org), but this should 
be further studied. This result opens the door to study the use of the Ca37 mAb against other important Candida 
species, which could be especially critical in the case of C. auris, due to its high antifungal resistance profile27.
The expression pattern of Adh1 protein was also analysed in different media and growth phases, showing a 
slight, non-significant changes in expression depending on the medium and growth phase. These results agree 
with a previously reported study28, where a constant Adh1 expression was found by analyzing mRNA. Although 
not being great differences, our results show more reactivity in stationary phase of cells grown in some media, 
which may be related to the fact that Adh2 has been described to be expressed only in the stationary phase28,29. 
Although we used yeast CWP for the expression study, we cannot totally rule out the possibility that the mAb is 
also recognizing some of the Adh2 protein.
Surprisingly, the IIF did not show any recognition of the fungus over short incubation times unless there was 
prior removal of carbohydrates, suggesting that these molecules prevent mAb binding. However, after an incu-
bation of 18 h the antibody was able to bind both fungal morphologies, although not uniformly. This may indi-
cate that the epitope is partially obscured by carbohydrates, and considering the high immunogenicity recently 
described for this protein the hypothesis seems plausible25. On the other hand, the ADH1 null mutant was recog-
nized by the antibody in spite of its lack of Adh1 protein. The ability of the Ca37 to bind hyphae is not surprising, 
as we found that Adh2 is present in the CWP fraction of that morphology. However, the unexpected recognition 
of the yeasts would need further investigation to elucidate whether Adh2 might be overexpressed in order to 
compensate the absence of Adh1.
The activity of the mAb against C. albicans could not be observed on actively growing yeasts, but a small inhi-
bition of 20% in germination was found. This contrasts with a recent study30 showing a decreased hyphal forma-
tion by an ADH1 null mutant. However, in this article, the authors suggest that the inhibition of hyphal formation 
is due to a decreased intracellular ATP content and the suppression of a signalling pathway controlling various 
virulence factors, which would be related to the cytosolic role of the Adh1, whereas Ca37 antibody will presum-
ably act only upon Adh1 protein present in the cell wall. On the contrary, when the yeast was incubated with the 
mAb in DPBS before inoculation onto Sabouraud Dextrose agar (SDA) plates, the inhibition percentages reached 
70 to 90% compared to the control. Other authors have achieved similar rates of inhibition against C. albicans 
Figure 5. Effect of ADH1 gene deletion and Ca37 monoclonal antibody on Galleria mellonella survival. (a) 
Larvae inoculated with DAY286, ADH1 knockout and ADH1 revertant C. albicans strains. P value was 0.0198 
when comparing DAY286 with knockout and 0.0350 when comparing it with revertant strain. (b) C. albicans 
yeast were pre-treated with the mAb, fluconazole or a non-specific IgG1 isotype control. Yeast cells were pre-
treated/incubated with 20 and 10 μg/mL of the mAb, 10 μg/mL of IgG1 isotype, fluconazole, or PBS alone (C. 
albicans control) for 18 h at 37 °C before been injected into larvae. Significant differences were found between 
C. albicans control and mAb pre-treated C. albicans groups (P < 0.001 in both cases). (c) Larvae treated with 
PBS (C. albicans control), 10 μg/mL Ca37 antibody or fluconazole after C. albicans infection (double injection). 
Significant differences were found between C. albicans control and antibody treatment (P = 0.0052) or 
fluconazole treatment (P < 0.001). Data from a single representative experiment (n = 16). Data were analysed 
using the Mantel-Cox test in GraphPad Prism software. Alpha value was set to 0.05. Non-injected and PBS 
injected larvae were used as viability control.
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using monoclonal antibodies (63%, 74–92% and 55–100%), but the mAb concentration used was between 2.5 to 
10 times higher than the concentration tested in this study31–33.
As the use of antifungal drugs at high doses can lead to hepatic and nephrotoxicity, synergistic ability between 
Ca37 and commonly used antifungals was also tested. It was found that the MIC values for amphotericin B and 
fluconazole were reduced to half in the strains used. Therefore, the antibody showed an additive effect, which 
might be of high relevance for clinicians, reducing high dose-associated adverse effects of antifungal drugs. It was 
shown that ADH1 is upregulated in yeast treated with fluconazole34, which could explain the observed effect of 
the mAb. In the case of the fluconazole-resistant strain, this effect was not enough to reduce the in vitro MIC to a 
therapeutically successful concentration (2 mg/L or less35). However, the antibody might render some strains with 
intermediate susceptibility more sensitive to the action of this antifungal. Nevertheless, this concept needs to be 
tested and confirmed. Other studies have already shown that a combination of a mAb and an antifungal drug can 
enhance the survival of mice infected with Candida5.
In the in vivo assessment, it is worth noting that the fungal density used was much higher than the one used for 
the in vitro tests, but larvae possess hemocytes and antimicrobial peptides that help them overcome infections36, and 
to survive to high inoculums of C. albicans (104 yeast/larva)37. In these assays, the importance of the Adh1 for fungal 
virulence was shown, as G. mellonella larvae infected with a C. albicans ADH1 null mutant strain exhibited pro-
longed survival in comparison to the larvae infected with the parental strain. The group treated with the single allele 
revertant strain also lived longer than the group infected with the parental strain but it was slightly more pathogenic 
than the null mutant strain. In this strain, only one allele of the ADH1 gene was reintroduced into the knockout 
mutant22, which may account for the failure to reach parental strain pathogenicity and fall as an intermediate. Song 
et al.30 also found that Adh1 is important for C. albicans pathogenicity, as they showed that survival of larvae, but 
also mice infected with an ADH1 null mutant, was increase in comparison to the infected with the wild type strain.
Then, the ability of Ca37 to increase larvae survival was explored, both as pre-treatment of the yeasts before 
infection and as treatment for larvae. In both cases, an increase of G. mellonella survival was observed, by 5 
days in larvae injected with pre-treated yeasts, and one day in mAb treated larvae after C. albicans inoculation, 
compared to larvae injected with the control fungus. This enhanced survival rate was similar to that observed 
with fluconazole treatment in both cases. It may also be that a higher or additional dose of the mAb may provide 
additional protection as a therapeutic. In the future, it would be interesting to study the additive effect of Ca37 
with fluconazole, to determine whether a lower dose of drug could be protective in combination with the mAb, 
or whether G. mellonella infected with a fluconazole resistant strain could be recovered in the presence of Ca37.
Despite the promising results showed in this study, several questions should be addressed in the future. It 
would be interesting to deepen into the role of the Adh2 in virulence by constructing an ADH2 and a double 
ADH1/ADH2 null mutant, to elucidate whether the lack of Adh1 is compensated by Adh2, to study the effect of 
the Ca37 mAb in opsonization and phagocytosis, and to confirm the protective effect of the Ca37 mAb in a mice 
model.
In conclusion, the results presented here show that the Ca37 mAb, developed against Adh1 protein, is able to 
inhibit the growth of C. albicans in vitro, and to improve the survival of G. mellonella in vivo. Moreover, it acts in 
an additive way with amphotericin B and fluconazole, leading to a reduction of the MIC by half compared to the 
control. Therefore, although further research is needed to corroborate its efficacy in animal models and define its 
mechanism/s of inhibition, this study, together with studies of other authors, indicates that C. albicans Adh1 may 
represent an interesting therapeutic target and, as it does not bind to human Adh1 protein, that the Ca37 mAb is 
a candidate for further in-depth studies as an alternative and safe treatment.
Methods
Microorganisms and human cell line culture. Nine Candida albicans strains were used in this study: 
NCPF 3153, a reference strain; CECT 13062 strain, isolated from systemic candidiasis; UPV 93–153, a fluconazole 
resistant strain; UPV 15–170, UPV 15–171 and UPV 15–172 strains, isolated from oral candidiasis and kindly 
provided by Cristina Marcos-Arias from the Department of Immunology, Microbiology and Parasitology of the 
University of the Basque Country (UPV/EHU); and DAY286, ADH1 knockout and revertant strains, obtained as 
described in Mukherjee et al.22. In addition to C. albicans, other three Candida species were used, C. parapsilosis 
ATCC 22019, C. glabrata ATCC 90030 (kindly provided by Dr. Dolores Moragues from the UPV/EHU) and C. 
auris CJ-197, isolated form an outbreak in La Fe Univeristy and Polytechnic Hospital (Valencia), which was a kind 
gift from Dr. Javier Pemán. The use of clinical strains from patients that had previously signed an anonymous 
informed consent form was approved by the Ethics Committee of the University of the Basque Country. All iso-
lation methods were carried out in accordance with relevant guidelines and regulations.
For obtaining yeast cells, an overnight culture was inoculated with 105 blastospores/mL in SDB and grown at 
37 °C with agitation. Yeasts were always grown in this medium unless otherwise stated. For supporting the growth 
of the DAY286 and its derived ADH1 knockout and revertant strains, histidine (100 µg/mL) was added to SDB. 
Hyphae were obtained by incubating yeast cells in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) 
for 4 h at 37 °C with agitation.
THP-1 human monocyte cell line were obtained from the American Type Culture Collection and cultured 
in RPMI 1640 supplemented with 10% FBS and L-glutamine (2 mM), penicillin (10000 U/mL), streptomycin 
(10 mg/mL), amphotericin B (25 μg/mL) and β-mercaptoetanol (0.05 mM), in a 5% CO2 atmosphere at 37 °C. 
Subcultures were made when cell density reached 106 viable cell/mL.
Production of Adh1 recombinant protein and anti-Adh1 (Ca37) monoclonal antibody. The C. 
albicans CECT 13062 ADH1 gene was cloned into pETBlue-2 vector (Novagen, Madison, WI, USA) and intro-
duced into Escherichia coli Turner (DE3) pLac cells (Novagen). Protein expression was induced by addition of 
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1 mM IPTG and purification was performed by affinity chromatography (HisTrap FF crude kit, GE Healthcare, 
Chicago, IL, USA). Finally, the obtained Adh1 was treated with Polymyxin B for endotoxin removal.
The production of the anti-Adh1 Ca37 mAb was carried out in BALB/C mice by the hybridoma production 
technology at Abyntek Biopharma Company (Technology Park, Zamudio, Spain), using purified Adh1 for the 
immunization process. Briefly, splenocytes were fused with Sp2/0 myeloma cells and the most reactive clones 
were selected by enzyme-linked immunosorbent assay (ELISA). The antibodies were purified by protein G chro-
matography. For this study, an IgG1 isotype-producer hybridoma was selected.
In order to avoid antibody aggregates, the mAb was treated using a thermal-cycling method as in Sadavarte 
and Ghosh38 and filtered before use.
Growth curves of yeast cells in different media. C. albicans CECT 13062 yeast cells where incubated at 
106 cell/mL in four different media; minimal medium supplemented with 0.5% glucose, 1% glucose and 2% glu-
cose and in SDB. Minimal medium was composed of yeast nitrogen base (1.34%) and Biotin (0.02%). The yeasts 
were incubated at 37 °C and the 600 nm absorbance (Nanophotometer, Implen, Munich, Germany) was measured 
each hour. Absorbance data was translated into cell density. Yeast cells were harvested by centrifugation at 10,000 
xg for 10 min at the middle of the exponential phase (8 h since the beginning of the incubation) and at the station-
ary phase (27 h since the beginning of the incubation). Yeast cell pellets were stored at −20 °C until further use.
Protein extraction, electrophoresis (SDS-PAGE and 2-DE), western blotting and Liquid chro-
matography–mass spectrometry (LC-MS/MS) identification. Protein extraction was performed as 
described in Pitarch et al.13. Briefly, yeast or hyphal cells were mixed with glass beads and disrupted using a 
Millmix 20 BeadBeater cell disruptor (Tehtnica, Železniki, Slovenia) for 20 min at 30 Hz. Then, they were centri-
fuged in order to separate the cytosolic fraction (supernatant) from the cell wall (pellet). This pellet was treated 
with SDS extraction buffer for 10 min at 100 °C, then centrifuged and the supernatant was collected to obtain the 
CWP fraction. In the case of THP-1 cells, the followed procedure was similar, but with slight changes. Specifically, 
they were disrupted only for 2 minutes in the BeadBeater, centrifuged and only the soluble fraction was recovered 
for analysis.
For the SDS-PAGE, protein samples were loaded into 10% acrylamide gels and run at 70 mA, 100 W and 200 V 
for 45 min in a Miniprotean II (Bio-Rad, Hercules, CA, USA), using the Page Ruler Plus as protein standard 
(Thermo Fisher Scientific, Waltham, MA, USA). For 2-DE, the protocol described by Pellon et al.39 was followed, 
but using 7 cm long Immobiline Drystrip gels (GE Healthcare) for the isoelectric focusing (IEF), under the fol-
lowing conditions: rehydration for 12 h, 500 V for 2000 Vhr, 1000 V for 3000 Vhr, 5000 V for 10 000 Vhr, and 
5000 V for 40000 Vhr. The proteins were then separated by SDS-PAGE. For protein identification, 2-DE gels were 
stained with Coomassie Brilliant Blue G25040.
To carry out the WB, proteins were transferred to Amersham Hybond-P PVDF membranes (GE Healthcare) 
for 1 h at 400 mA. Then, WB was performed using 30 μg/mL of Ca37 mAb at 37 °C for 1.5 h as primary antibody 
and an anti-mouse IgG-HRP diluted 1:100,000 for 45 min as secondary. Membranes were developed using the 
ECL prime (GE Healthcare) in a G:BOX Chemi system (Syngene, Cambridge, United Kingdom). All the incuba-
tion steps were carried out at room temperature unless otherwise indicated. The analysis of 2-DE and WBs was 
carried out by image analysis using ImageMaster 2DPlatinum Software (GE Healthcare).
The selected protein spots were manually excised from Coomassie Brilliant Blue G250 stained gels and identi-
fied by LC-MS/MS in the proteomics service of the UPV/EHU, SGIker, as described in Pellon et al.39.
Indirect immunofluorescence. Fungal cells were used for detection using Ca37 by IIFs. They were carried 
out on cells treated with sodium metaperiodate (50 mM) to remove cell wall carbohydrates, and on non-treated 
cells. Then, 100 µg/mL of Ca37 mAb at 37 °C for 1.5 h or at 4 °C for 18 h were added as primary antibody, and 
anti-mouse IgG-FITC (4 μg/mL) diluted in PBS containing 0.05% (w/v) Evans Blue and 0.05% (v/v) Tween 20 
for 30 min at 37 °C as secondary. Cells were observed under a fluorescent Eclipse Ni microscope (Nikon, Tokio, 
Japan), and images taken with a Zyla sCMOS camera (Andor, Belfast, UK).
Inhibitory effect of Ca37 monoclonal antibody on fungal growth and germination. For testing 
the effect of the antibody on the growth of C. albicans, 100 μL of 1.5 ×103 yeast/mL in SDB were added to each 
well of a 96-well plate. SDB alone was used as blank and C. albicans without mAb was included as a growth con-
trol. Ten microliters of the antibody were added in a range from 10 μg/mL to 1 pg/mL. The plates were incubated 
at 37 °C and the absorbance at 600 nm measured every 10 min for 24 h (Synergy HT, BioTek, Winooski, VT, USA). 
Absorbance data from three different experiments were used and translated into densities.
To test the ability of the mAb to inhibit non-actively growing yeast, the procedure described by Mangliani 
et al.41 was followed. Briefly, 1.5 × 103 yeast/mL were pre-incubated in DPBS for 18 h at 37 °C at 120 rpm with the 
same range of antibody concentrations mentioned above. Then, 100 μL of each treatment were inoculated onto 
SDA plates, in triplicate, so that the CFUs could be counted.
To study the effect of the Ca37 on C. albicans germination, suspensions of yeasts at 1.5 × 103 yeast/mL were 
incubated in RPMI 1640 supplemented with 10% FBS, alone or with 20 or 10 µg/mL of mAb for 4 h at 37 °C and 
120 rpm. Then, cells were fixed with 10% formalin saline and the percentage of germinated yeast was estimated by 
counting with an inverted optical microscopy.
Measure of Minimal Inhibitory Concentration (MIC). The effect of Ca37 mAb in combination with 
amphotericin B and fluconazole was studied following the guidelines of EUCAST42 using C. albicans CECT 13062 
and fluconazole-resistant UPV 93–153 strains, and 20, 10, 2, 1 and 0 µg/mL concentrations of antibody.
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The plates were incubated for 24 or 48 h at 37 °C, and absorbance recorded at 530 nm. The FICI was calculated 
using the derived MICs according to Bardbari et al.43.
Insect infection studies. In this study G. mellonella infection model was used. Sixth-instar larvae (Grubco 
Company, Fairfield, OH, USA or Bichosa and Mundo Gusano, Vitoria, Spain) were injected with 106 cells of C. 
albicans in 10 µL PBS through the last right pro-leg. Sixteen larvae were used per group, and two negative control 
groups were included: non-injected and PBS injected group. Larvae were incubated at 37 °C and checked daily 
over 7 days44. At least two independent experiments were performed (n ≥ 32).
Initially, DAY286, ADH1 knockout and an ADH1 revertant strain were used, following the procedure 
described above, to study the effect of the absence of the ADH1 gene on yeast virulence. To observed the effect of 
the mAb, yeasts were treated for 18 h at 37 °C with Ca37 (20 and 10 μg/mL), a non-specific IgG1 isotype control 
from murine myeloma (Sigma-Aldrich, 10 μg/mL), fluconazole (13.86 μg/mL) or DPBS before using the treated 
C. albicans to inoculate G. mellonella. Conversely, we also studied the therapeutic effect of Ca37 by infecting 
larvae with C. albicans in the last right pro-leg followed by provision of 10 μL of the mAb (12 mg/kg), fluconazole 
(14 mg/kg) or PBS in the last left pro-leg. Once all the larvae were infected, C. albicans (pre- and not pre-treated) 
cells were inoculated into SDA in order to obtain a CFU count and make sure that 106 cells/larva had been pro-
vided to all the groups.
Statistical analysis. All data are presented as mean ± standard error. The statistical analyses were carried 
out using IBM SPPS statistics 22 (Professional Statistic, Chicago, IL, USA). Normality of data was checked using 
the Shapiro Wilks test and homogeneity of the variance using the Levene test. Normal data were analyzed using 
one-way ANOVA test (one-tailed test), with Bonferroni’s or Tamhane’s T2 corrections for multiple comparisons. 
In the case of the G. mellonella survival curves, Mantel-Cox test in GraphPad Prism software was used. Alpha 
value was set at 0.05, and the exact P values for each statistical analysis are showed in the text or figure legends.
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